Evolent Health, Inc.EVH

NYSEIndustrialsServices-Management Services
Price (close)
$3.52
Market cap
$396.1M
P/E
—
Revenue (TTM)
$2.1B
Net income
-$505.0M
Dividend yield
—
1-year total return
-60.5%
Net margin
-24.1%
Revenue growth
-4.5%
Debt / equity
2.52x

What Evolent Health, Inc. does.

Evolent is a market leader in connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. We work on behalf of health plans and other risk-bearing entities and payers (our customers) to support physicians and other healthcare providers (our users) in providing high quality evidence-based care to their patients. We believe adherence to evidence-based clinical pathways supports better outcomes for patients, a better experience for physicians, and lower costs for the healthcare system overall.

Specialty care represents a significant and fast-growing portion of healthcare costs in the United States, driven in part by the pace of development of new therapies and treatments. To manage these increasing costs, some health plans and other risk-bearing entities historically deployed cost containment strategies that can limit access to care and operate in narrow silos (for example, prior authorization for radiological studies being considered independently from a comprehensive chemotherapy regimen). We believe Evolent can bring an integrated approach to a patient’s condition across multiple specialties, using technology to recommend our evidence-based clinical pathways in a way that provides rapid feedback to the provider, seeks to remove barriers to care, and aligns financial incentives with the best evidence.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$924.6M$908.0M$1.4B$2.0B$2.6B$1.9B
Net income-$334.2M-$37.6M-$19.2M-$113.0M-$61.6M-$534.5M
Free cash flow——————

More on EVH.

Figures from Evolent Health, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.